Longer-term (96-week) efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in women

被引：0
|
作者：
Kityo, C. [1 ]
Hagins, D. [2 ]
Koenig, E. [3 ]
Avihingsanon, A. [4 ]
Chetchotisakd, P. [5 ]
Supparatpinyo, K. [6 ]
Gankina, N. [7 ]
Pokrovsky, V. [8 ]
Voronin, E. [9 ]
Stephens, J. L. [10 ]
DeJesus, E. [11 ]
Wang, H. [12 ]
Acosta, R. [12 ]
Brainard, D. [12 ]
Martin, H. [12 ]
Makadzange, T. A. [12 ]
机构：
[1] Joint Clin Res Ctr, Kampala, Uganda
[2] Chatham Care Ctr, Georgia Dept Publ Hlth, Savannah, GA USA
[3] Inst Dominicano Estudios Virol IDEV, Dr Pineyro 211, Santo Domingo, Dominican Rep
[4] Thai Red Cross AIDS Res Ctr, HIV Netherlands Australia Thailand Res Collaborat, Bangkok, Thailand
[5] Srinagarind Hosp, Khon Kaen, Thailand
[6] Chiang Mai Univ, Chiang Mai, Thailand
[7] Krasnoyarsk Terr Ctr Prevent & Control AIDS & Inf, Krasnoyarsk, Russia
[8] Ctr Prevent & Control AIDS, Moscow, Russia
[9] Republican Clin Infect Hosp, Minist Hlth Russian Federat, Fed State Inst, St Petersburg, Russia
[10] Mercer Univ, Sch Med, Macon, GA 31207 USA
[11] Orlando Immunol Ctr, Orlando, FL USA
[12] Gilead Sci, Foster City, CA USA
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
MOAB0106
引用
收藏
页码：4 / 4
页数：1
相关论文
共 50 条
  • [21] A study of the pharmacokinetics, safety, and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed pregnant women with HIV
    Zhang, Haeyoung
    Hindman, Jason T.
    Lin, Ludwig
    Davis, Maggie
    Shang, Justin
    Xiao, Deqing
    Avihingsanon, Anchalee
    Arora, Priyanka
    Palaparthy, Ramesh
    Girish, Sandhya
    Marathe, Dhananjay D.
    AIDS, 2024, 38 (01) : F1 - F9
  • [22] Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults
    Raffi, Francois
    Orkin, Chloe
    Clarke, Amanda
    Slama, Laurence
    Gallant, Joel
    Daar, Eric
    Henry, Keith
    Santana-Bagur, Jorge
    Stein, David K.
    Bellos, Nicholaos
    Scarsella, Anthony
    Yan, Mingjin
    Abram, Michael E.
    Cheng, Andrew
    Rhee, Martin S.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2017, 75 (02) : 226 - 231
  • [23] IMPACT OF COADMINISTRATION WITHOUT OR WITH FOOD ON THE 96-WEEK EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE (TAF) IN VIRALLY SUPPRESSED CHRONIC HBV PATIENTS SWITCHED FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) TO TAF
    Kao, Jia-Horng
    Chuang, Wan-Long
    Chen, Chi-Yi
    Ahn, Sang Hoon
    Fung, Scott K.
    Elkhashab, Magdy
    Hann, Hie-Won L.
    Ravendhran, Natarajan
    Nguyen, Tuan T.
    Tan, Susanna
    Flaherty, John F.
    Gagger, Anuj
    Gao, Bing
    Brainard, Diana M.
    Phan, Charles G.
    Lim, Young-Suk
    Ferret, Maria Asuncion Buti
    Lampertico, Pietro
    HEPATOLOGY, 2020, 72 : 484A - 484A
  • [24] Week 96 Results of Bictegravir/Emtricitabine/Tenofovir Alafenamide for HIV Treatment in People With Substance Use Disorders
    Havens, Joshua P.
    Bares, Sara H.
    Lyden, Elizabeth
    Fadul, Nada
    Swindells, Susan
    OPEN FORUM INFECTIOUS DISEASES, 2025, 12 (01):
  • [25] Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIV
    Rolle, Charlotte-Paige
    Nguyen, Vu
    Patel, Kiran
    Cruz, Dan
    DeJesus, Edwin
    Hinestrosa, Federico
    MEDICINE, 2021, 100 (38)
  • [26] Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG) plus F/TAF or DTG plus F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance
    Acosta, Rima K.
    Willkom, Madeleine
    Andreatta, Kristen
    Liu, Hui
    Martin, Ross
    Parvangada, Aiyappa
    Martin, Hal
    Collins, Sean
    White, Kirsten L.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2020, 85 (03) : 363 - 371
  • [27] Viro-Immunological Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide among Women Living with HIV: A 96-Week Post-Switch Analysis from the Real-Life SHiNe-SHiC Cohort
    Colpani, Agnese
    De Vito, Andrea
    Marino, Andrea
    Ceccarelli, Manuela
    Celesia, Benedetto Maurizio
    Conti, Giuseppe Nicolo
    Spampinato, Serena
    Moi, Giulia
    Venanzi Rullo, Emmanuele
    Pellicano, Giovanni Francesco
    Sofia, Sonia Agata
    Panto, Grazia
    Iacobello, Carmelo
    Frasca, Chiara Maria
    Montineri, Arturo
    Albanese, Antonio
    Angioni, Goffredo
    Cacopardo, Bruno
    Madeddu, Giordano
    Nunnari, Giuseppe
    BIOMEDICINES, 2024, 12 (10)
  • [28] Enhanced metabolic health and immune response with bictegravir/emtricitabine/TAF: Insights from a 96-week retrospective study
    Spampinato, Serena
    Conti, Giuseppe Nicolo
    Marino, Andrea
    Raimondo, Vincenzo
    Celesia, Benedetto Maurizio
    Pellicano, Giovanni Francesco
    Puci, Mariangela Valentina
    Sotgiu, Giovanni
    Bruno, Roberto
    Villari, Nunziatina
    Mirabile, Alessia
    Coco, Viviana Agata Maria
    Raddusa, Michele Salvatore Paterno
    Pistara, Eugenia
    Boscia, Vincenzo
    Fisicaro, Viviana
    Fiorenza, Giorgia
    Cacopardo, Bruno
    Rullo, Emmanuele Venanzi
    Nunnari, Giuseppe
    BIOMEDICAL REPORTS, 2024, 21 (06)
  • [29] The effect of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) on whole-body insulin sensitivity in volunteers without HIV
    Heskin, Joseph
    Movahedi, Roya
    Kang, Sujin
    Byrne, Ruth
    Elecito, Krestine
    Gridel, Perrine
    Marchesani, Paola
    Moyle, Graeme
    Milinkovic, Ana
    Boffito, Marta
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 257 - 258
  • [30] Week 48 outcomes from the BRAAVE 2020 study: a randomised switch to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in African American adults with HIV
    Hagins, D.
    Kumar, P.
    Wurapa, A.
    Brar, I.
    Berger, D.
    Osiyemi, O.
    Hileman, C.
    Ramgopal, M.
    McDonald, C.
    Blair, C.
    Andreatta, K.
    Collins, S. E.
    Brainard, D.
    Gohlar, G.
    Martin, H.
    HIV MEDICINE, 2021, 22 : 33 - 34
12345